Obsidian Therapeutics

Congratulations to Rachel Burga, Shreyas Dahotre, Tyler Humpton, Lauren McLaughlin, Theresa Ross, Dhruv Sethi, and Nirzari Shah on their recent promotions! Thank you all for the value you bring every day and the positive impact you’ve had thus far. We look forward to your continued growth and success!   #Promotions #Obsidianrocks 

Today our CEO, Madan Jagasia, will be presenting at the Immuno-Oncology Summit at 4:10pm in Philadelphia, PA. His talk is titled, “Improving Efficacy and Minimizing Safety Risks of TIL Cell Therapy by Rational Engineering of TIL”. Check out the full agenda: https://lnkd.in/erZ7p5x

Welcome to our most recent hires – we’re honored that you’ve chosen to join us, and excited about what we can achieve together! #obsidianrocks 

We are pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to OBX-115 for the treatment of patients with metastatic or locally advanced melanoma that is refractory to or has relapsed after PD-1/PD-L1–based immune checkpoint inhibitors (ICI). “FDA Fast Track Designation underscores the ongoing unmet need for patients with melanoma that has progressed on or after ICI therapy, agnostic of mutational status, and that OBX-115 may have the potential to address that unmet need,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. “OBX-115 is poised to be a transformative treatment option due to its patient-centric focus, including compatibility with core needle biopsy tumor tissue procurement and positively differentiated safety and tolerability profile relative to non-engineered TIL cell therapy. We are highly encouraged by the most recent safety and efficacy data presented at the 2024 American Society of Clinical Oncology Meeting. With this designation, we look forward to continued collaborative interaction with the FDA as we advance OBX-115 clinical development in the broad post-ICI setting.” Learn more here: https://lnkd.in/evryhXp3

Obsidian Therapeutics is growing! We have an exciting Process Engineer, External Manufacturing/MSAT opportunity open on Jeff Holderness's growing MSAT team! In this position you will be collaborating with our internal CMC team and with our external CDMOs. Learn more and apply today at https://lnkd.in/g2fgvS97 Please note that we are not in need of any agency support on this search at this time. Thank you!

We’re excited to develop rising talent and lucky to have worked with our Spring 2024 Co-Ops: Saumil (Analytical Development), Vatsal (Process Development), and Katie (Cell Therapy). Shout out to our committed mentors Sean, Zheng, Farris and Ning! And wishing our Co-ops all the best in your future endeavors! #mentors #coops #northeasternuniversity 

Obsidianites joined with colleagues from Nimbus Therapeutics and ROME Therapeutics and 300 other groups to celebrate and support the LGBTQ+ community at the Boston Pride For The People Parade on June 8th. #pride

Obsidianites joined with colleagues from Nimbus Therapeutics and ROME Therapeutics and 300 other groups to celebrate and support the LGBTQ+ community at the Boston Pride For The People Parade on June 8th. #pride

We are excited to announce the appointment of William Pao, M.D., Ph.D., to Obsidian’s Board of Directors. “Obsidian’s tumor-infiltrating lymphocyte cell therapy is unique and has the potential to deliver a transformative treatment option to address the unmet need of patients with immune checkpoint inhibitor-resistant solid tumors,” added Dr. Pao. “I am excited to bring my experience in oncology drug development to Obsidian’s board and help guide the company’s next phase of growth.” Read more here: https://lnkd.in/gW9Mw64z

Today at #ASCO we are presenting additional OBX-115 safety and efficacy data in an oral presentation, to be delivered by Dr. Amaria, the principal investigator on the OBX-115 first-in-human clinical trial. Dr. Amaria commented, “OBX-115 continues to demonstrate positive safety and efficacy data in additional patients, which is encouraging, given this is a heavily pre-treated patient population with advanced disease. Unfortunately, late-line systemic therapy options offer limited benefit, with ORR of approximately 10% and mPFS of approximately 2–3 months. It is exciting to see a potential new option emerge for these patients with a positively differentiated safety profile and promising early activity achieved without IL2.” Learn more here: https://lnkd.in/eE7zXjz6